Details for New Drug Application (NDA): 077702
✉ Email this page to a colleague
NDA 077702 describes NEVIRAPINE, which is a drug marketed by Aurobindo, Cipla, Alvogen, Apotex, Aurobindo Pharma, Macleods Pharms Ltd, Mylan, Pharmobedient, Sandoz, Tech Organized, Apotex Inc, Hetero Labs Ltd Iii, Micro Labs Ltd, Mylan Pharms Inc, Prinston Inc, and Strides Pharma, and is included in twenty-three NDAs. It is available from six suppliers. Additional details are available on the NEVIRAPINE profile page.
The generic ingredient in NEVIRAPINE is nevirapine. There are twenty drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the nevirapine profile page.
The generic ingredient in NEVIRAPINE is nevirapine. There are twenty drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the nevirapine profile page.
Summary for 077702
| Tradename: | NEVIRAPINE |
| Applicant: | Aurobindo |
| Ingredient: | nevirapine |
| Patents: | 0 |
Suppliers and Packaging for NDA: 077702
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NEVIRAPINE | nevirapine | SUSPENSION;ORAL | 077702 | ANDA | Aurobindo Pharma Limited | 65862-057 | 65862-057-11 | 100 mL in 1 BOTTLE (65862-057-11) |
| NEVIRAPINE | nevirapine | SUSPENSION;ORAL | 077702 | ANDA | Aurobindo Pharma Limited | 65862-057 | 65862-057-24 | 240 mL in 1 BOTTLE (65862-057-24) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION;ORAL | Strength | 50MG/5ML | ||||
| Approval Date: | May 22, 2012 | TE: | AA | RLD: | No | ||||
Complete Access Available with Subscription
